All the news Showing 10 of 78 articles from: Triple therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection Liz Highleyman / 22 October 2013 The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a ... Simeprevir with interferon effective in genotype 4 HCV infection and for HIV/HCV co-infected people with genotype 1 hepatitis C Liz Highleyman / 21 October 2013 Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS ... Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen Liz Highleyman / 10 October 2013 A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, whilst an interferon-free regimen containing daclatasvir, asunaprevir and BMS-791325 produced sustained ... Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection Medivir press release / 27 September 2013 Patients with recurrent HCV benefit from triple therapy after liver transplant Healio Hepatology / 17 September 2013 Telaprevir safe, effective among older patients with chronic HCV Healio Hepatology / 31 July 2013 Are Patients Receiving the Latest Anti-HCV Drugs? AGA Journals blog / 22 July 2013 Drug interactions may compromise response to boceprevir and telaprevir Liz Highleyman / 17 June 2013 Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C virus ... Telaprevir-based triple-drug therapy benefits CHC patients with ESRD Internal Medicine News / 12 June 2013 Boceprevir benefits null, partial responders to prior HCV therapy with peginterferon/ribavirin Healio Hepatology / 12 June 2013 ← Prev1...23456...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive